AU747391B2 - Pharmaceutical composition comprising factor VIII and neutral liposomes - Google Patents

Pharmaceutical composition comprising factor VIII and neutral liposomes Download PDF

Info

Publication number
AU747391B2
AU747391B2 AU34414/99A AU3441499A AU747391B2 AU 747391 B2 AU747391 B2 AU 747391B2 AU 34414/99 A AU34414/99 A AU 34414/99A AU 3441499 A AU3441499 A AU 3441499A AU 747391 B2 AU747391 B2 AU 747391B2
Authority
AU
Australia
Prior art keywords
fviii
pharmaceutical composition
composition according
colloidal particles
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34414/99A
Other languages
English (en)
Other versions
AU3441499A (en
Inventor
Liliana Bar
Moshe Baru
Israel Nur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Biopharmaceuticals Patents Ltd
Original Assignee
Opperbas Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding BV filed Critical Opperbas Holding BV
Publication of AU3441499A publication Critical patent/AU3441499A/en
Application granted granted Critical
Publication of AU747391B2 publication Critical patent/AU747391B2/en
Assigned to ZILIP PHARMA B.V. reassignment ZILIP PHARMA B.V. Alteration of Name(s) in Register under S187 Assignors: OPPERBAS HOLDING B.V.
Assigned to CANTAB BIOPHARMACEUTICALS PATENTS LIMITED reassignment CANTAB BIOPHARMACEUTICALS PATENTS LIMITED Alteration of Name(s) in Register under S187 Assignors: ZILIP PHARMA B.V.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU34414/99A 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor VIII and neutral liposomes Ceased AU747391B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
IL124224 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (2)

Publication Number Publication Date
AU3441499A AU3441499A (en) 1999-11-16
AU747391B2 true AU747391B2 (en) 2002-05-16

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34414/99A Ceased AU747391B2 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor VIII and neutral liposomes

Country Status (12)

Country Link
US (2) US6593294B1 (cg-RX-API-DMAC10.html)
EP (1) EP1079805B1 (cg-RX-API-DMAC10.html)
JP (1) JP4545928B2 (cg-RX-API-DMAC10.html)
AT (1) ATE283034T1 (cg-RX-API-DMAC10.html)
AU (1) AU747391B2 (cg-RX-API-DMAC10.html)
BR (1) BR9909978A (cg-RX-API-DMAC10.html)
CA (1) CA2329768C (cg-RX-API-DMAC10.html)
DE (1) DE69922189T2 (cg-RX-API-DMAC10.html)
ES (1) ES2233036T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA00010241A (cg-RX-API-DMAC10.html)
PT (1) PT1079805E (cg-RX-API-DMAC10.html)
WO (1) WO1999055306A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
PT1633440E (pt) * 2003-04-15 2008-08-25 Opperbas Holding Bv Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
WO2005017526A1 (en) * 2003-08-05 2005-02-24 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
PL1713446T3 (pl) * 2004-01-23 2011-05-31 Camurus Ab Nielamelarne trójskładnikowe kompozycje lipidów
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
BRPI0612843A2 (pt) * 2005-06-29 2010-11-30 The Research Foundation Of State University Of New York composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP2007357B1 (en) * 2006-03-30 2016-11-09 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
JP5860409B2 (ja) 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
MXPA00010241A (es) 2004-09-06
EP1079805A1 (en) 2001-03-07
AU3441499A (en) 1999-11-16
CA2329768A1 (en) 1999-11-04
CA2329768C (en) 2008-06-10
ATE283034T1 (de) 2004-12-15
DE69922189D1 (de) 2004-12-30
US6930087B2 (en) 2005-08-16
BR9909978A (pt) 2000-12-26
JP2002512947A (ja) 2002-05-08
WO1999055306A1 (en) 1999-11-04
PT1079805E (pt) 2005-03-31
JP4545928B2 (ja) 2010-09-15
ES2233036T3 (es) 2005-06-01
US6593294B1 (en) 2003-07-15
DE69922189T2 (de) 2005-11-10
EP1079805B1 (en) 2004-11-24
US20030134778A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US6593294B1 (en) Pharmaceutical composition comprising Factor VIII and neutral liposomes
JP2001181214A (ja) リポゾームマイクロレシーバー組成物および方法
JP2024532164A (ja) 血友病ａの治療における使用のための修飾コロイド粒子
JP7573582B2 (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
Scott et al. Therapy of von Willebrand disease
EP1407780B1 (en) Pharmaceutically stable hemostatic compositions
US20030232075A1 (en) Compositions for producing factor Xa
ES2307009T3 (es) Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales.
US20030147944A1 (en) Lipid carrier compositions with protected surface reactive functions
IL139053A (en) Pharmaceutical composition comprising factor VIII and neutral colloidal particles
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
JP2002060345A (ja) 血液凝固能異常に係わる疾患の予防・治療剤
Lisman et al. Mechanism of action of recombinant activated Factor VII
EP1635861A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
JP2024532163A (ja) 血友病ａの治療における使用のための修飾コロイド粒子

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired